Medicare to Restrict Coverage of Anti-Amyloid Antibody Therapy for Alzheimer’s Patients

By Jeffrey Gelblum, MD As a practicing neurologist with over 25 years of experience treating Alzheimer’s disease, I strongly oppose the proposed intention of Centers for Medicare & Medicaid Services (CMS) to restrict coverage of anti-amyloid antibody therapy to only those patients who must participate in an approved hospital-based clinical trial (Coverage with Evidence Development, …

Medicare to Restrict Coverage of Anti-Amyloid Antibody Therapy for Alzheimer’s Patients Read More »